Efficacy and safety of hypoglycemic drugs in children with type 2 diabetes mellitus

被引:11
作者
Benavides, S
Striet, J
Germak, J
Nahata, MC
机构
[1] Ohio State Univ, Coll Pharm, Div Pharm Practice & Adm, Columbus, OH 43210 USA
[2] Ohio State Univ, Coll Med, Columbus, OH 43210 USA
[3] Childrens Hosp, Childrens Res Inst, Columbus, OH 43205 USA
[4] Childrens Hosp, Div Pediat Endocrinol, Columbus, OH 43205 USA
来源
PHARMACOTHERAPY | 2005年 / 25卷 / 06期
关键词
type 2 diabetes mellitus; hemoglobin A(1c); glycosylated hemoglobin; A1C; metformin; insulin; sulfonylureas; pediatric patients;
D O I
10.1592/phco.2005.25.6.803
中图分类号
R9 [药学];
学科分类号
1007 [药学];
摘要
Study Objectives. To assess the characteristics of children with type 2 diabetes mellitus and to determine the efficacy and safety of drug therapies for this disease in this population. Design. Retrospective review of medical records. Setting. Endocrinology specialty clinic at a tertiary teaching children's hospital. Patients. Forty-two children and adolescents with type 2 diabetes examined between January 1996 and December 2001. Measurements and Main Results. Demographic information, presenting signs and symptoms, drug history, and laboratory values were obtained in all patients. Presenting signs and symptoms were similar to those seen in adults. Patients were initially treated with metformin (14.3%), sulfonylureas (14.3%), insulin (31.0%), or combination therapy (14.3%). Most drug regimens decreased hemoglobin A(1c) (A1C) levels. Overall, patients treated with drugs had a significant decrease in A1C values, from 10.6% +/- 2.7% (mean +/- SD) before treatment to 8.0% +/- 2.0% at 3.2-52.9 months of treatment (p < 0.001). Adverse reactions attributed to drugs included hypoglycemia and gastrointestinal distress. Conclusion. Drug therapy appears to be effective in lowering A1C values in pediatric patients, although further prospective trials are necessary to determine optimal drug therapy in this population.
引用
收藏
页码:803 / 809
页数:7
相关论文
共 16 条
[1]
American Diabetes Association, 2002, DIABETES CARE S1, V25, pS90
[2]
[Anonymous], 2000, Pediatrics, V105, P671
[3]
*BRIST MYERS SQUIB, 2004, GLUC GLYB METF HCI T
[4]
Type 2 diabetes among North American children and adolescents: An epidemiologic review and a public health perspective [J].
Fagot-Campagna, A ;
Pettitt, DJ ;
Engelgau, MM ;
Burrows, NR ;
Geiss, LS ;
Valdez, R ;
Beckles, GLA ;
Saaddine, J ;
Gregg, EW ;
Williamson, DF ;
Narayan, KMV .
JOURNAL OF PEDIATRICS, 2000, 136 (05) :664-672
[5]
The effects of metformin on body mass index and glucose tolerance in obese adolescents with fasting hyperinsulinemia and a family history of type 2 diabetes [J].
Freemark, M ;
Bursey, D .
PEDIATRICS, 2001, 107 (04) :E55
[6]
Effect of metformin in pediatric patients with type 2 diabetes - A randomized controlled trial [J].
Jones, KL ;
Arslanian, S ;
Peterokova, VA ;
Park, JS ;
Tomlinson, M .
DIABETES CARE, 2002, 25 (01) :89-94
[8]
Increased incidence of non-insulin-dependent diabetes mellitus among adolescents [J].
PinhasHamiel, O ;
Dolan, LM ;
Daniels, SR ;
Standiford, D ;
Khoury, PR ;
Zeitler, P .
JOURNAL OF PEDIATRICS, 1996, 128 (05) :608-615
[9]
Emerging Epidemic of type 2 diabetes in youth [J].
Rosenbloom, AL ;
Joe, JR ;
Young, RS ;
Winter, WE .
DIABETES CARE, 1999, 22 (02) :345-354
[10]
Ryan EA, 2004, DIABETES CARE, V27, P2282, DOI 10.2337/diacare.27.9.2282